Zofran (ondansetron) MDL Continues to Grow

More and more parents are filing lawsuits against GlaxoSmithKline LLC (“GSK”), maker of anti-nausea drug Zofran (ondansetron), after their children exposed to the drug were born with birth defects. The drug, approved by the FDA to only treat nausea and vomiting in cancer patients undergoing chemotherapy and patients who had major surgeries, has been marketed for expectant mothers “off label” to treat similar symptoms associated with pregnancy. Plaintiffs claim that Zofran (ondansetron) caused their children’s birth defects, such as cleft palate and congenital heart defects, and that GSK failed to properly warn about the drug’s risks. Over 230 lawsuits alleging similar claims have been centralized into a multi-district litigation, or MDL, under Judge F. Dennis Saylor in the District of Massachusetts—lawsuits GSK moved to dismiss in January 2016 but was denied after Judge Saylor ruled that the families were entitled to a chance to develop their case.

Plaintiffs’ firm Grant & Eisenhofer filed some of the first cases in the Zofran (ondansetron) MDL, and serves as co-lead on the Plaintiffs’ Executive Committee. If you or a loved one took Zofran (ondansetron) for morning sickness during your first trimester and your baby was born with a cleft palate or congenital heart defect, please contact us at 877-978-0169 for a confidential evaluation of your potential claim.

Real Time Analytics